The present invention is directed to the anti-DR5 antibody mAb 1 and mAb 2, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to DR5-binding molecules that comprise fragments of such molecules, and to bispecific molecules, including diabodies, BiTEs, knobs/holes bispecific antibodies, etc., that comprise: (i) such DR5 -binding fragments and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell.La présente invention concerne lanticorps anti-DR5 mAb 1 et mAb 2, et des versions humanisées et chimériques de tels anticorps. Linvention concerne en outre des molécules de liaison de DR5 qui comprennent des fragments de telles molécules, et des molécules bispécifiques, comprenant des diabodies, des BiTes, des anticorps bispécifiques knob/hole, etc., qui comprennent : (i) de tels fragments de liaison de DR5 et (ii) un domaine capable de se lier à un épitope dune molécule présente sur la surface dune cellule effectrice.
